Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Sarcoma 1

Conditions

Rhabdomyosarcoma 1Lung Neoplasms 1

Interventions

pembrolizumab 259Cyclophosphamide 243Specimen Handling 198fludarabine 174Magnetic Resonance Spectroscopy 173Biopsy 147Nivolumab 121Carboplatin 99Radiotherapy 92Paclitaxel 88venetoclax 82Cisplatin 82Gemcitabine 79fludarabine phosphate 78Injections 69Ipilimumab 64Dexamethasone 62atezolizumab 59Cetuximab 58Bevacizumab 58Radiation 56Fluorouracil 56Azacitidine 56durvalumab 54Radiosurgery 53Temozolomide 47Rituximab 44Oxaliplatin 44Docetaxel 44Irinotecan 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × mocetinostat × 1 year × Clear all
NCT03220477 2025-08-06

Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.

Memorial Sloan Kettering Cancer Center

Phase 1 Active not recruiting
28 enrolled
Thoracic

Lung Neoplasms

NCT04299113 2025-06-26

Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma

Jonsson Comprehensive Cancer Center

Phase 1 Active not recruiting
38 enrolled
Sarcoma

Rhabdomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡